Indeed, pharmacological inhibition of RIPK1 kinase activity has been shown to be effective in the murine CD4+CD45RBHI T-cell transfer model of colitis and provided dose-dependent protection from inflammatory cell death in NemoVillin.cre/+ mice [213]. Here, RIPK1 is linked to colitis.